New therapies for asthma

Trends in Molecular Medicine

Volumn 12, Issue 11, 2006, Pages 515-520

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AL 438; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CARMOTEROL; CHEMOKINE RECEPTOR ANTAGONIST; CICLESONIDE; CORTICOSTEROID; CORTICOSTEROID DERIVATIVE; CYTOKINE ANTIBODY; ENZYME ACTIVATOR; ETANERCEPT; FORMOTEROL; GSK 159797; HISTONE DEACETYLASE 2 ACTIVATOR; IMATINIB; INDACATEROL; INFLIXIMAB; INTERLEUKIN 5 ANTIBODY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL STIMULATING AGENT; SALMETEROL; TACHYKININ RECEPTOR ANTAGONIST; THYMIC STROMAL LYMPHOPOIETIN ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RETENTION; DRUG TARGETING; GROWTH RETARDATION; HUMAN; LONG TERM CARE; NONHUMAN; PRESCRIPTION; REVIEW; RHINITIS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; HUMANS; INFLAMMATION MEDIATORS; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION;

EID: 33750285456     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.09.006     Document Type: Review

References (47)

1. Heaney L.G., et al. Severe asthma treatment: need for characterising patients. Lancet 365 (2005) 974-976
2. Wenzel S. Severe asthma in adults. Am. J. Respir. Crit. Care Med. 172 (2005) 149-160
3. 2-agonists and corticosteroids. Eur. Respir. J. 19 (2002) 182-191
4. Barnes P.J. New drugs for asthma. Nat. Rev. Drug Discov. 3 (2004) 831-844
5. 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs 14 (2005) 775-783
6. Barnes P.J., et al. How do corticosteroids work in asthma?. Ann. Intern. Med. 139 (2003) 359-370
7. Reynolds N.A., et al. Ciclesonide. Drugs 64 (2004) 511-519
8. Barnes P.J. How corticosteroids control inflammation. Br. J. Pharmacol. 148 (2006) 245-254
9. Schacke H., et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 227-232
10. Rosen J., et al. The search for safer glucocorticoid receptor ligands. Endocr. Rev. 26 (2005) 452-464
11. Barnes P.J., et al. Inflammatory mediators of asthma: an update. Pharmacol. Rev. 50 (1998) 515-596
12. Barnes P.J. Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev. 14 (2003) 511-522
13. Leckie M.J., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 356 (2000) 2144-2148
14. Kips J.C., et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 167 (2003) 1655-1659
15. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol. Rev. 202 (2004) 175-190
16. Berry M.A., et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N. Engl. J. Med. 354 (2006) 697-708
17. Erin E.M., et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am. J. Respir. Crit. Care Med (2006) 10.1164/rccm.200601-072OCv1
18. Reber L., et al. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur. J. Pharmacol. 533 (2006) 327-340
19. Liu Y.J. Thymic stromal lymphopoietin: master switch for allergic inflammation. J. Exp. Med. 203 (2006) 269-273
20. Bryan S., et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperreactivity and the late asthmatic response. Lancet 356 (2000) 2149-2153
21. Lukacs N.W., et al. Chemokines and their receptors in chronic pulmonary disease. Curr. Drug Targets Inflamm. Allergy 4 (2005) 313-317
22. Erin E.M., et al. Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr. Drug Targets Inflamm. Allergy 1 (2002) 201-214
23. Barnes P.J. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol. Ther. 109 (2006) 238-245
24. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 (2005) 167-175
25. Bousquet J., et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 61 (2006) 72-78
26. Houslay M.D., et al. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 10 (2005) 1503-1519
27. Barnes P.J. Transcription factors in airway diseases. Lab. Invest. 86 (2006) 867-872
28. Karin M., et al. The IKK NF-κB system: a treasure trove for drug development. Nat. Rev. Drug Discov. 3 (2004) 17-26
29. Kumar S., et al. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2 (2003) 717-726
30. Duan W., et al. Inhaled p38α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am. J. Respir. Crit. Care Med. 171 (2005) 571-578
31. Bochner B.S. Adhesion molecules as therapeutic targets. Immunol. Allergy Clin. North Am. 24 (2004) 615-630
32. Singh J., et al. Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma. Curr. Top. Med. Chem. 4 (2004) 1497-1507
33. Strunk R.C., et al. Omalizumab for asthma. N. Engl. J. Med. 354 (2006) 2689-2695
34. Wong B.R., et al. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin. Investig. Drugs 13 (2004) 743-762
35. Stenton G.R., et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J. Immunol. 169 (2002) 1028-1036
36. Meltzer E.O., et al. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J. Allergy Clin. Immunol. 115 (2005) 791-796
37. Rosenwasser L.J., et al. Anti-CD23. Clin. Rev. Allergy Immunol. 29 (2005) 61-72
38. Rosenwasser L.J., et al. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J. Allergy Clin. Immunol. 112 (2003) 563-570
39. Akdis M., et al. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J. Allergy Clin. Immunol. 116 (2005) 961-968
40. Wohlleben G., et al. Atopic disorders: a vaccine around the corner?. Trends Immunol. 22 (2001) 618-626
41. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5 (2006) 471-484
42. Feleszko W., et al. Toll-like receptors-novel targets in allergic airway disease (probiotics, friends and relatives). Eur. J. Pharmacol. 533 (2006) 308-318
43. Barnes P.J., et al. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 364 (2004) 985-996
44. Barnes P.J. Reduced histone deacetylase in COPD: clinical implications. Chest 129 (2006) 151-155
45. Cosio B.G., et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood monocytes in asthma. Am. J. Respir. Crit. Care Med. 170 (2004) 141-147
46. Cosio B.G., et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 200 (2004) 689-695
47. Barnes P.J. Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment. Expert Opin. Ther. Targets 9 (2005) 1111-1121